Drosophila melanogaster is emerging as a valuable genetic model system for the study of mental retardation (MR). MR genes are remarkably similar between humans and fruit flies. Cognitive behavioral assays can detect reductions in learning and memory in flies with mutations in MR genes. Neuroanatomical methods, including some at single-neuron resolution, are helping to reveal the cellular bases of faulty brain development caused by MR gene mutations. Drosophila fragile X mental retardation 1 (dfmr1) is the fly counterpart of the human gene whose malfunction causes fragile X syndrome. Research on the fly gene is leading the field in molecular mechanisms of the gene product's biological function and in pharmacological rescue of brain and behavioral phenotypes. Future work holds the promise of using genetic pathway analysis and primary neuronal culture methods in Drosophila as tools for drug discovery for a wide range of MR and related disorders.
T he past decade has produced a dramatic rise in publications revealing genetic and molecular mechanisms of mental retardation (MR). Nonetheless, MR remains the most common medical condition for which no specific drug treatments are available. In contrast, disorders with similar prevalence, such as heart failure and schizophrenia, stimulate vigorous drug discovery and development efforts in the academic and pharmaceutical sectors [Scatton and Sanger, 2000; Tang and Francis, 2003] . At the present time, three major factors represent obstacles to thinking of MR as treatable in the pharmacological sense. For each obstacle, the Drosophila melanogaster genetic model system offers valuable strategies for overcoming the challenge. First, MR disorders have diverse environmental and hereditary etiologies, diagnostic criteria vary among clinicians, and MR is often associated with other neurological manifestations [Hodapp and Dykens, 2005] . This might lead one to the pessimistic, but premature conclusion that hundreds of different drugs would be needed to treat cognitive dysfunction in the majority of MR patients. Second, in most cases, there is limited understanding of how neuronal phenotypes, if they are known at all, disrupt functional brain circuitry and thereby diminish MR patients' cognitive capacities. Third, standard bioassays, such as proliferation, apoptosis, and biochemical tests on tumor cell lines for screening potential anticancer agents, are just beginning to be developed for MR disorders [Bourtchouladze et al., 2003] . This article will summarize published studies from the Drosophila system relevant to the biology of MR and present arguments for its expanded use as a step toward therapeutic drug screening in mammals.
RATIONALE FOR STUDYING MR IN DROSOPHILA
One might wonder, "How would you recognize a mentally retarded fruit fly?" Cognitive functions can be measured in insects, and deviations from normal, whether due to hereditary or environmental factors, can be quantified. Drosophila manifest a wide range of experience-dependent behaviors. This behavioral plasticity has been used both to identify and to characterize genetic mutants, starting with the pioneering work of Seymour Benzer and colleagues [Dudai et al., 1976; Greenspan, 1995] . Molecular analysis of these genes has revealed that mechanisms of learning and memory are shared between vertebrates and invertebrates [Mayford and Kandel, 1999] .
At the simple end of the behavioral spectrum, wild-type Drosophila habituate to sensory stimuli [Engel and Wu, 1996; Cho et al., 2004] . In addition, they can learn associations across sensory modalities and remember them for varying amounts of time depending on the nature and duration of the training [Connolly and Tully, 1998 ]. For example, flies learn to avoid an odor that has been paired with electric shock (classical olfactory conditioning) or a spatial location where they were exposed to a noxious heat stimulus (operant place learning). When the task is made more complex by the addition of irrelevant sensory stimuli, flies can still learn the relevant predictive cue [Liu et al., 1999] . In an even more complex form of behavioral plasticity, when the sexual advances of a male fruit fly are rebuffed by a nonreceptive female, the male responds with a prolonged reduction in his courtship activity (courtship conditioning) [Tompkins et al., 1983; Mehren et al., 2004] .
For each task a fly can learn, the level of initial learning and its retention during specific phases of memory, including shortand long-term, are differentially affected by single-gene mutations [Dubnau and Tully, 1998 ]. Moreover, different forms of learning and memory require different brain structures [Heisenberg, 2003] . Hence, while we do not know whether natural populations of fruit flies include "mentally retarded" individuals, scientists can identify flies in the laboratory that have specific, quantifiable cognitive impairments and these are likely to result from distinct biochemical and neuroanatomical mechanisms.
Despite the hundreds of millions of years of evolutionary distance that separate Homo sapiens and Drosophila melanogaster, MR-associated molecules are remarkably well conserved between the two species. In a recent comparative sequence analysis of nearly 300 molecularly identified human MR genes, we found that 87% have a highly similar relative in Drosophila [Inlow and Restifo, 2004] . This percentage is higher than previous reports that used the same sequence-similarity criteria to compare Drosophila genes and human disease genes of diverse types [Fortini et al., 2000; Reiter et al., 2001] . Furthermore, the extent and type of amino acid sequence similarity between the human MR genes and their fruit fly counterparts were sufficient in 76% to suggest that they have similar biological functions in the two species [Inlow and Restifo, 2004] . The bestcharacterized Drosophila MR gene counterpart is Drosophila fragile X mental retardation 1 (dfmr1), mutations of which cause a syndrome of behavioral and cognitive deficits, neuroanatomical abnormalities, and male sterility (discussed below).
Five of the fruit fly counterparts of human MR genes are already known to be essential for normal learning and memory (Table 1 ). In two cases (FLNA/ cheerio and RSK2/rsk; nomenclature is presented throughout as human gene abbreviation/fly gene abbreviation [see Inlow and Restifo, 2004 , for additional information regarding the similarities between the human and fly genes]), the genes were identified in traditional unbiased screens for behavioral phenotypes due to loss-of-function mutations [Dubnau et al., 2003; Putz et al., 2004] . In the other cases, gain-of-function mutations (GNAS1/Gs␣60A) or loss-of-function mutations (NF1/Nf1 and Fmr1/dfmr1) were created or selected because of an interest in a specific gene and then tested for their behavioral consequences [Connolly et al., 1996; Guo et al., 2000; McBride et al., 2005] . As noted in Table  1 , several different learning-and-memory paradigms were used to demonstrate deficits in the Drosophila mutants. In the one case for which mutants of the same gene were subjected to more than one type of test (RSK2/rsk), deficits were seen in both types [Putz et al., 2004] . Taken together, the data demonstrate that these Drosophila mutants are cognitively impaired and, even without a systematic scheme for measuring performance across the full spectrum of fruit fly abilities (i.e., a Drosophila "intelligence quotient test"), it is reasonable to consider the five genes involved to be "Drosophila MR genes." Furthermore, given the known neurological phenotypes of other MR gene counterparts in Drosophila [Inlow and Restifo, 2004 and references therein] , it is easy to predict that many more human MR genes will eventually be shown to have conserved cognitive functions in fruit flies.
New MR genes are being published at a rate of one to three per month, but hundreds more remain to be identified [Inlow and Restifo, 2004] . Increasingly effective gene-mapping methods, as well as candidate-gene approaches, are in use to achieve these goals [Ropers and Hamel, 2005] . Morley and Montgomery [2001] proposed human counterparts of Drosophila learning or memory genes as candidates for genes affecting human cognition. Given the examples in Table  1 , one could easily propose that all entries on the rapidly expanding list of fly learning and memory genes [Roman and Davis, 2001; Waddell and Quinn, 2001; Dubnau et al., 2003] should be considered MR gene candidates.
POWER AND POTENTIAL OF THE FLY GENETICS TOOLBOX
The experimental power and sophistication of the Drosophila genetic system has been detailed elsewhere [Greenspan, 1997; Sullivan et al., 2000] , but several features with special relevance to developmental brain disorders warrant mention here. First, phenotypic analysis of developmental mutations is easier than in mammals. Because Drosophila are not viviparous, developmental phenotypes of lethal mutants are more accessible. These phenotypes provide clues to gene function that are unsuspected in hereditary disorders that cause human fetuses to die early in gestation. In addition, one can create a series of mutant alleles with a spectrum of severities to study the consequences of varying levels of residual gene function. Extremely clever methods, with origins in yeast genetics, allow the revelation of cell-autonomous neuronal phenotypes, at very high resolu- [Venturin et al. 2004] .
tion, in single-cell mutant clones . The relative simplicity of the Drosophila genome often permits single counterparts of a mammalian gene family to be studied without the complications of genetic redundancy that result from duplications that occurred during vertebrate evolution [Holland et al., 1994; Durand, 2003] . For example, unlike the three closely related Fmr1 genes in mammals, only one is present in Drosophila [Wan et al., 2000] . On the other hand, one can not assume that the single fly gene's function represents the sum of the multiple mammalian genes' functions. Second, the ability to regulate gene expression in time and space using transgenic Drosophila [McGuire et al., 2004] offers an important means of determining when and where a gene is acting to promote cognitive function-which has major implications for therapeutic intervention strategies. If transgenic rescue of a mutant fly with a wild-type allele is successful only when the transgene is active during development, then that gene is critical for functional brain asssembly but is not necessarily required in the mature animal for synaptic plasticity. Conversely, if mutant performance can be enhanced by providing the wild-type protein acutely before behavioral testing, that would indicate that the gene serves ongoing functions during adulthood. For example, the learning deficits of Drosophila Nf1 mutants can be rescued by inducing expression of wild-type Nf1 in the adult, suggesting that Nf1 function during development is not essential for adult learning [Guo et al., 2000] . Similar distinctions can be made when determining the critical period for the cognition-impairing effects of dominant gain-of-function mutations. In addition, RNA interference methods can be used to induce a loss-of-function condition at specific times [e.g., Lam and Thummel, 2000 ] to determine the consequences of acutely eliminating a gene product in an otherwise normal animal.
Third, Drosophila genetics can be used to identify members of metabolic, regulatory, or signaling pathways. This results from a basic principle that mutations in genes that are members of the same biological pathway often share phenotypes. The pathway concept is important in part because, when an individual human gene has a counterpart in Drosophila, other members of its pathway often do as well. For instance, MR is a consequence of mutations in over a dozen genes involved in protein glycosylation, all of which have fruit fly counterparts [see Appendix of Inlow and Restifo, 2004] . Furthermore, pathways tend to intersect or converge, especially as signals are transmitted from the cell surface to regulators of enzyme activity or gene expression. For example, mutations in several highly conserved genes of the Rho-type small-G-protein signaling cascade (OPHN1/Graf; GDI1/Gdi; ARHGEF6/rtGEF) cause isolated MR [Ramakers, 2002] . Downstream of this pathway lies the previously mentioned MR gene RSK2 (see Table 1 ) whose gene product phosphorylates the transcription factor CREB (a keystone of mammalian and invertebrate learning [Mayford and Kandel, 1999] ), whose partners include CREB binding protein (CBP), product of the Rubinstein-Taybi syndrome MR gene (CREBBP/nejire). Genetic screens in Drosophila can reveal previously unknown members of a pathway and cross-pathway relationships, for instance by identifying new mutations causing synergistic enhancement or suppression of a phenotype [Bonini, 2000] . Drosophila CBP is an important regulator of the hedgehog pathway [Akimaru et al., 1997] , whose vertebrate counterparts include several MR genes (SHH/hedgehog; PTCH/patched; GLI3/cubitus interruptus; ZIC2/oddpaired), which suggests a connection between CBP and SHH pathways in mammals that could be relevant to MR. Why do these pathway relationships matter? For the simple but powerful reason that a drug that acts on a well-placed pharmacological target could provide effective treatment for disorders resulting from mutations of many different genes throughout one complex pathway.
Fourth, the Drosophila system could also be applied to environmental causes of MR, in particular pre-or perinatal exposure to neurotoxic drugs of abuse that alter brain development [Stanwood and Levitt, 2004] . Adult fruit flies respond to cocaine and ethanol in timeand dose-dependent ways that are reminiscent of mammalian responses, including behavioral intoxication, sensitization, and tolerance, and the genetic control of these responses is beginning to be elucidated [McClung and Hirsh, 1998; Guarnieri and Heberlein, 2003 ]. Extending genetic studies in Drosophila to the neurodevelopmental effects of ethanol and cocaine could suggest treatment strategies for acquired as well as hereditary MR. There is already one demonstration of a link, albeit a complex one, between the genetics of ethanol tolerance and the genetics of cognition in Drosophila. Mutations of a neuropeptide-encoding gene were independently identified in screens for memory deficits (amnesiac alleles) and for enhanced ethanol sensitivity (the cheapdate allele) [Quinn et al., 1979; Feany and Quinn, 1995; Moore et al., 1998] . The neuropeptide appears to have both developmental and adult functions because ethanol hypersensitivity could be rescued by providing the wildtype gene to adults [Moore et al., 1998 ], whereas rescue of the memory phenotype required wild-type gene expression during development [DeZazzo et al., 1999] .
Finally, and perhaps most important, enthusiasm for using Drosophila in the study of MR is bolstered by the recent development of fly models of neurodegenerative disorders and successful drug treatment to normalize behavioral and anatomical phenotypes [Bonini and Fortini, 2003] . Drosophila models of Parkinson's disease include both transgenic flies expressing ␣-synuclein with a human disease-associated dominant mutation [Feany and Bender, 2000] , as well as wild-type flies exposed to the pesticide rotenone [Coulom and Birman, 2004] . In the former case, as in humans with familial Parkinson's disease, mutant ␣-Synuclein protein aggregates within dopaminergic brain neurons, causing adult-onset degeneration and locomotor abnormalities [Feany and Bender, 2000] . Overexpression of Parkin protein suppresses ␣-Synuclein-induced neurodegeneration in both cultured mammalian neurons and mutant flies [Petrucelli et al., 2002; Haywood and Staveley, 2004] . In addition, geldanamycin, a modulator of stress-response pathways, prevents agedependent dopaminergic cell loss in these ␣-synuclein transgenic flies [Auluck and Bonini, 2002] .
Equally compelling data come from the Drosophila model of Hunting-. . . the Drosophila system could also be applied to environmental causes of MR, in particular pre-or perinatal exposure to neurotoxic drugs of abuse . . .
ton's disease (HD), created by expression of human mutant Huntingtin protein with a polyglutamine-tract expansion, which causes repeat-length-dependent neuronal degeneration [Jackson et al., 1998 ]. Three biochemical approaches to modulating HD pathology have similar beneficial effects in rodent and Drosophila models [Steffan et al., 2001; Hockly et al., 2003; Ravikumar et al., 2004; Steffan et al., 2004] . In addition, the fly system has begun to suggest new pharmacological strategies and specific chemical compounds that could ultimately yield effective treatments for neurodegenerative diseases in humans [Auluck and Bonini, 2002; Kazantsev et al., 2002] .
CASE IN POINT: DROSOPHILA FRAGILE X MENTAL RETARDATION 1 (dfmr1)
Fragile X syndrome (FXS), a very common MR disorder with cytogenetic and neurodevelopmental manifestations, was covered in detail in a recent dedicated issue of this journal edited by Crnic and Hagerman [see MRDDRR volume 10, issue 1, 2004] . FXS patients have loss-of-function mutations of Fmr1, which causes a distinctive profile of cognitive deficits of varying severity, along with enlarged testes, characteristic facies, and, in some patients, other neurological features such as autism, epilepsy, and disordered sleep [Hagerman, 2002; Cornish et al., 2004] . Evidence from both mammalian and fly systems strongly supports a working model in which FMRP's primary neuronal function is selective RNA binding and transport to dendrites, for the purpose of translational controlmainly repression-of specific proteins in a synaptic activity-dependent manner [Darnell et al., 2004; Willemsen et al., 2004] . This would put FMRP, and localized translation, at the center of synaptic plasticity mechanisms in both developing and mature animals.
Activation of metabotropic glutamate receptors (mGluR), specifically the Gp1 class, regulates FMRP localization and perisynaptic translation [Weiler et al., 1997 [Weiler et al., , 2004 Todd et al., 2003; Antar et al., 2004] . In addition, mGluR-mediated long-term depression at hippocampal synapses is increased in Fmr1 mutant mice [Huber et al., 2002] . These observations have led to the proposal that FXS neurobehavioral manifestations result from excessive mGluR signaling [Bear et al., 2004] , which suggests that Gp1 mGluR antagonists could provide effective treatment for the disorder.
The Drosophila gene product, dFMRP, is very similar in sequence and domain organization to its mammalian counterparts, with Ն70% amino acid identity in the RNA-binding KH domains and ribosome-interaction domain [Wan et al., 2000] . It is found throughout the central nervous system (CNS) and peripheral nervous system (PNS) of developing and mature animals, primarily in the cytoplasm of (probably all) neuronal somata [Zhang et al., 2001; Morales et al., 2002; Lee et al., 2003; Pan et al., 2004] , but not in glia. Immunoelectron microscopy localization methods would be required to rule out small amounts of dFMRP in neuronal nuclei or near postsynaptic sites, as was found in mammals [Feng et al., 1997] .
The neurological phenotypes of dfmr1 mutants include behavioral and cognitive deficits. The most compelling of these, in terms of comparison to human FXS, is very rapid memory loss in the courtship conditioning assay, recently reported by McBride and Jongens and their colleagues. After rejection by an unreceptive female during a 1-hour training period, mutant males reduce their courtship activity to the same degree as do wild-type males, demostrating intact learning [McBride et al., 2005] . However, within minutes thereafter, the mutants resume courtship at their prior baseline level, revealing a profound short-term memory deficit. This inability to suppress a behavior might also represent a form of perseveration. Short-term memory for complex tasks is one of the specific weaknesses of the human FXS cognitive profile [Cornish et al., 2004] . In addition, lack of behavioral inhibition, which often results in perseveration, has been proposed as a fundamental underlying deficit in FXS [Cornish et al., 2004] . Because dfmr1 mutant performance on other tasks has not yet been reported, it is too early to conclude anything about the scope and specificity of the cognitive deficit. Nonetheless, the nature of the memory deficit in the fly mutants suggests a qualitative overlap with FXS patients' cognitive weaknesses. Another major recent advance has been the pharmacological rescue of the dfmr1 memory deficit by treatment with mGluR antagonists [McBride et al., 2005] , discussed below.
Drosophila dfmr1 mutants also have circadian rhythm defects, notably poor rhythmicity of locomotor behavior. Because the eclosion of the locomotor rhythm is intact, (the emergence of the adult fly from its protective cocoon-like structure at the end of metamorphosis) the locomotor rhythm defect reflects abnormal output of the circadian clock rather than a broken central oscillator [Dockendorff et al., 2002; Inoue et al., 2002; Morales et al., 2002] . This phenotype is reminiscent of the aberrant sleep patterns and elevated melatonin levels found in FXS males [Gould et al., 2000] . Finally, "courtship interest" is reduced in dfmr1 mutant males [Dockendorff et al., 2002] , but the residual level can still be reduced further by courtship conditioning [McBride et al., 2005] . As with the memory defect, courtship interest was restored by mGluR blockade during development or adulthood, whereas the activity rhythm phenotype was not [McBride et al., 2005] .
In humans, Fmr1 mutations do not cause major disruptions in brain structure, although modest quantitative changes have been noted by magnetic resonance imaging (MRI) in some regions and these changes correlate with cognitive deficits [Hessl et al., 2004] . However, at the single-neuron level (using the Golgi impregnation technique on postmortem brain tissue), cortical neurons in several regions have abnormal dendrites, with spines showing excessive numbers and length [Rudelli et al., 1985; Hinton et al., 1991; Wisniewski et al., 1991; Irwin et al., 2001] . Similar studies in the Fmr1 mutant mouse confirmed these findings, as well as excessive dendritic branching [Comery et al., 1997; Irwin et al., 2002; Galvez et al., 2003] . Given that spines are postsynaptic sites and that dendrites undergo complex alterations during development [Cline, 2001] , it is not surprising that a "subtle" morphological change would cause serious functional consequences. The abnormal spine appearance has been interpreted as immaturity or stalled development, possibly due to insufficient pruning [reviewed in Beckel-Mitchener and Greenough, 2004], but it may reflect synaptic loss [Bear et al., 2004] . Moreover, real-time analyses of GFPlabeled cortical neurons of Fmr1 mutant mice are more consistent with abnormal timing and speed of dendritic development [Nimchinksy et al., 2001] , suggesting that this issue needs further investigation. Note that neither axonal projection patterns nor axon terminal-arbor morphology has been examined in Fmr1 mutant mammals.
The cellular neural phenotypes of dfmr1 mutant flies are qualitatively similar to the mammalian ones, with a common-but not universal-theme of dendritic and axonal overgrowth in CNS and PNS, as well as pathfinding errors [Zhang et al., 2001; Dockendorff et al., 2002; Morales et al., 2002; Lee et al., 2003; Michel et al., 2004; Pan et al., 2004] . The only neurons for which both axonal and dendritic morphologies have been examined in dfmr1 mutants are those of the mushroom bodies, a brain region well known for its role in many forms of associative learning and memory [Zars, 2000; Roman and Davis, 2001; Heisenberg, 2003] . Carlos Michel and Robert Kraft in my lab found a specific developmental defect during the metamorphic transition [Michel et al., 2004] , when hundreds of mushroom body ␣/␤ neurons are born and differentiate . Wild-type ␣/␤ axons bifurcate at right angles and project into vertical (␣) and medial (␤) lobes. In dfmr1 mutants, axons project into the lobes at the appropriate developmental stage but, as they approach the midline, they fail to detect or to obey a "stop " signal [Michel et al., 2004] . Rather, they continue growing into the contralateral hemisphere, resulting in the appearance of ␤-lobe midline fusion, observable by confocal microscopy with appropriate fluorescent markers (Fig. 1) . Three lines of evidence from other labs suggest that this mushroom body phenotype is the cause, at least in part, of the above-mentioned memory deficit. First, prevention of mushroom body development results in poor courtship conditioning memory [McBride et al., 1999] . Second, the Drosophila memory mutant linotte has the same mushroom body phenotype [Moreau-Fauvarque et al., 1998 ]. Third, the ␣/␤ lobes are required for memory retrieval [McGuire et al., 2001] .
How severe is ␤-lobe fusion in a fly relative to mammalian brain defects? Given the differences in absolute size and structural organization between mammalian and insect brains, the comparison is difficult. Nonetheless, roughly speaking, the ␤ lobes are comparable to a large bilaterally symmetric pair of axon tracts that can be visualized by MRI or histological staining, e.g., the internal capsule. In other words, if FXS brains had a defect comparable to ␤-lobe fusion, it would be relatively easy to detect without morphometric analysis. This, along with the other neuronal phenotypes (see below), suggests that dfmr1 mutants are neurologically more severely affected than are human or mouse Fmr1 mutants. Pan and colleagues [2004] used genetic techniques to create mosaic Drosophila in which single mushroom body neurons were dfmr1 mutant and surrounded by wild-type brain tissue. The mutant neurons had excessive and disordered branching of axons and dendrites. Conversely, overexpression of wild-type dfmr1 in mushroom body neurons reduced dendritic and axonal complexity to less than those of wildtype [Pan et al., 2004] . These data provide strong evidence that dfmr1 normally functions to limit the exuberance of axonal and dendritic branching, consistent with earlier observations in the PNS (see below). However, there is an important caveat when interpreting phenotypes in such mosaic animals, exemplified by the report that single-neuron dfmr1 mutant clones in the ␤ lobes do not show midline crossing [Pan et al., 2004] . This discrepancy provides an important clue, suggesting that the whole-brain mutant phenotype [Michel et al., 2004] is notcell-autonomous, but rather results from cell-cell interaction. The cell-autonomy issue has broader implications, for instance, for understanding the phenotypic variation of many X-linked MR disorders in heterozygous human females, whose brains are mosaic due to X-chromosome inactivation [e.g., Braunschweig et al., 2004] . Furthermore, while it is tempting to assume that mushroom body neuron dendrites and axons have excessive branching in whole-animal dfmr1 mutants, it would be prudent to determine their structure directly by using Golgi or another highresolution method.
Elsewhere in the brains of dfmr1 mutants, neurite extension defects were seen in DC neurons, which are important for emergence of the adult after metamorphosis, and in the circadianpacemaker LNv neurons [Morales et al., 2002] . Both types of neurons also showed pathfinding or projection errors, but their phenotypes differed in that DC neurons frequently showed reduced axon extension and ectopic branching, while the LNv neurons showed axon overextension but only rarely [Morales et al., 2002] . Given the complexity of CNS anatomy, the presence of phenotypes affecting many neuron types and the apparently nonautonomous behavior of ␣/␤ axons at the midline raise the nontrivial question of which phenotypes are primary and which are secondary to other defects.
In the PNS of dfmr1 mutant larvae, axon terminals at the neuromuscular junction are larger than normal, with similar increases in branch and synaptic bouton numbers [Zhang et al., 2001] . In other words, the junction is larger, but proportionately so. Neurotransmission from the larger junctions is also increased, indicating a roughly proportionate in- Fig. 1 . Abnormal mushroom body structure in dfmr1 mutants. Confocal micoroscopy analysis using anti-Fasciclin II to visualize the mushroom body ␣ and ␤ lobes. In the wildtype (A), the ␤ lobes approach, but stop before, the midline (arrow). In the dfmr1 mutant (B), the ␤-lobe axons have grown across the midline and fused with the contralateral fibers (arrow). [adapted from Michel et al., 2004] .
crease in functional synapses [Zhang et al., 2001] . On the sensory side, the phenotype is slightly different. Dendritic arbors of mutant larval body wall sensory neurons show increased higher-order branching, but remain restricted within their usual segment boundaries. Hence, the overall footprint of the arbor is normal, but within that region there are more terminal branches [Lee et al., 2003] . For both the motor neuron axon terminals and the sensory neuron dendrites, overexpression of wild-type dFMRP induces the corresponding opposite phenotypes, consistent with the conclusion that dfmr1 wild-type function is to limit the extent and complexity of a neuron's terminal arbors, whether axonal or dendritic.
Given these neuronal defects, it is not surprising that movement is adversely affected by dfmr1 mutations. Specifically, larval crawling is abnormally circuitous (although normal in speed), another indication of a more prominent neurological phenotype than in mammals. One might guess that this results from a combination of motor and sensory defects, but it can be rescued by selective expression of wild-type dfmr1 in the sensory neurons, suggesting that the altered locomotion is due primarily to aberrant sensory input to the motor system [Xu et al., 2004] . Adult flight performance is reduced in dfmr1 mutants [Zhang et al., 2001 ], but the underlying cause is unknown.
It is worth considering how similar fly and mammalian phenotypes need to be in order to validate the fly systemalthough it will be some time before a clear answer emerges. Take, for example, the fragile X testis phenotype. Both mammalian and fly mutants have testicular enlargement. In the former case, it occurs after puberty and is due to Sertoli cell hyperplasia [Slegtenhorst-Eegdeman et al., 1998 ], whereas in the latter it is seen transiently in young adults and caused by disorganized bundles of spermatids . Behavioral phenotypes are more difficult to compare. Is the reduced courtship interest of dfmr1 mutant males [Dockendorff et al., 2002] a reflection of reduced libido or is it a counterpart of social anxiety and avoidance seen in FXS males [Cornish et al., 2004] ? For now, I would argue that the phenotypic details may matter less than the molecular pathways underlying them, for, if mechanisms are similar, then drug-based treatments should be similar as well.
The recent successful pharmacological rescue of dfmr1 phenotypes takes the fly model of FXS one giant step forward. When dfmr1 mutant larvae are fed a diet supplemented with one of several mGluR antagonists (including both competitive and noncompetitive agents), the resulting adult flies show normal memory in the courtship conditioning assay and normal mushroom body morphology [McBride et al., 2005] . The further result of that study, showing that memory can be rescued by treating flies only as adults, is striking for two reasons. First, the developmental mushroom body defect is not reversed by the adult-treatment protocol, which is hardly surprising given the bulk of misdirected axonal projections that would have to be retracted. Second, and most important, the ability to achieve behavioral rescue by treating "postnatally"-without needing to "fix" a major morphological defect and without needing to replace the defective gene-gives great hope for effective postnatal therapies for developmental brain disorders. One is reminded of the extraordinary plasticity of young human brains that enables their functional reorganization after major trauma such as hemispherectomy [Vargha-Khadem et al., 1997] .
Biochemical studies revealed that dFMRP exerts translational control through RNA interference mechanisms [reviewed in Siomi et al., 2004] , and this led to similar findings for the mammalian protein. Drosophila FMRP associates with an RNA-induced silencing complex (RISC), through which cells destroy specific transcripts, and is also involved in microRNA pathways of translational repression [Caudy et al., 2002; Ishizuka et al., 2002; Schenck et al., 2003; Jin et al., 2004] . These studies led to the finding that mammalian FMRP associates with the microRNA pathway [Jin et al., 2004] . This is a clear case of the fly system leading, rather than merely following, the field.
Functionally relevant protein partners and target transcripts of dFMRP have also been identified using a combination of genetic and biochemical approaches. The first of these was futsch, which encodes the microtubule-associated protein MAP1B and has an NMJ mutant phenotype that is opposite of the dfmr1 phenotype; in double mutants, the two mutations suppress each others' effects and the resulting NMJ is close to normal [Zhang et al., 2001] . This led to the demonstration that dFMRP associates with futsch RNA and negatively regulates its translation [Zhang et al., 2001] . Two independent biochemical screens identified mammalian MAP1B transcripts as FMRP-associated [Kaytor and Orr, 2001] . Similarly, dFMRP associates with the fly counterpart of human CYFIPs (cytoplasmic FMRP-interacting proteins), which has mutant phenotypes that are generally opposite those of dfmr1 [Schenck et al., 2003 ]. In the sensory neurons whose dendritic arbors are controlled by dFMRP, the protein binds and negatively regulates transcripts encoding the GTPase Rac1 [Lee et al., 2003 ] and a degenerin/epithelial sodium channel family member [Xu et al., 2004] . Recently, a genetic screen for mutations that interact with dfmr1 revealed Lgl, encoded by lethal(2) giant larvae, as a close associate of FMRP in both flies and mice [Zarnescu et al., 2005] . Together, the available data point to considerable mechanistic similarities between fly and mammalian FMRP function.
In summary, neuroanatomical, behavioral, biochemical, and pharmacological data provide compelling support for the use of Drosophila as a genetic model system for fragile X syndrome and, indirectly, for other hereditary MR disorders as well.
PROSPECTS FOR DRUG DISCOVERY AND DEVELOPMENT
In light of the structural and functional similarities between human MR genes and their fruit fly counterparts, and the recent report of successful treatment of dfmr1 mutants, there is an extraordinary opportunity to use the Drosophila system as a drug-screening tool for MR. There are two general strategies for mon-. . . the ability to achieve behavioral rescue by treating "postnatally"-without needing to "fix" a major morphological defect and without needing to replace the defective gene-gives great hope for effective postnatal therapies for developmental brain disorders.
itoring effects of an MR-relevant drug: rescue of a mutant phenotype (whether at the biochemical, neuroanatomical or behavioral level) or modulation of the function of an identified drug target. In the first case, one need not know specific drug targets in advance and the mechanism of action is a secondary matter. In the second strategy, one needs an assay for the activity of the known target. In Drosophila, bioassays based on whole animals or on cultured cells each have particular advantages. For whole animals, there are multiple options for routes of drug administration, including feeding, topical application, injection, and aerosol exposure [e.g., Hirsh, 2000] . One can then assess the resulting behavior and brain structure as well as more general outcomes, such as viability, longevity, and fecundity. On the other hand, in vitro cell-based assays have the advantage of bypassing the anatomical barriers around the CNS, from integument and gastrointestinal tract to circulatory system and blood-brain barrier, structures that may differ considerably between insects and mammals. Furthermore, compared with whole-animal assays, cell-based assays are more likely to be amenable to automation and, hence, to higher-throughput screening methods.
Cellular assays can be divided into those using established cell lines and those using primary cells or tissues freshly explanted from wild-type or mutant animals. The Schneider-2 (S2) cell line, which can express transfected genes, has revealed molecular mechanisms of cell adhesion [Hortsch and Bieber, 1991] , much as Xenopus oocytes have done for ion channel function. Drosophila Neuroglian, whose human counterpart, L1 cell adhesion molecule (L1CAM/Nrg), is defective in a complex set of MR disorders [Weller and Gartner, 2001 ], controls axon pathfinding by regulating adhesive interactions between neurons [Hall and Bieber, 1997; Hortsch et al., 1998 ]. S2 cells expressing mutant forms of Neuroglian could be used to screen for drugs that restore cell adhesion. When S2 cells grow on a flat substrate they can be induced to send out long, thin processes, and this property has recently been exploited to demonstrate that dFMRPcontaining ribonucleoprotein granules are transported along microtubules in the neurite-like processes [Ling et al., 2004] . For now, this has been important for understanding dFMRP transport mechanisms, but it suggests that S2 cells with processes may provide a drug-screening tool for MR-related functions.
Primary culture methods have the obvious advantage of allowing the size, shape, and growth dynamics of actual neurons from intact animals to be assayed. We developed culture methods for genetically marked Drosophila mushroom body neurons harvested at specific developmental times. In vitro, these developmentally plastic neurons grow a neurite arbor with distinctive morphometric features and respond with greater outgrowth to physiological levels of an endogenous steroid hormone [Kraft et al., 1998 ]. Moreover, mutant neuronal phenotypes, including stunted growth, excessive growth, and altered branching structure, can be detected [Kraft R, Escobar M, Kurtis J, Restifo L, manuscript in preparation]. If mutations in Drosophila MR genes disrupt neuronal morphology in vitro, then cell culture could be used as a screening assay for drugs that normalize them.
CLOSING REMARKS: WHAT IS NEEDED TO OPTIMIZE THE VALUE OF THE FLY SYSTEM?
Despite the powerful genetic technology afforded by the Drosophila system, a number of additional or modified tools would greatly boost its value as a model for MR and other neurobehavioral disorders. In particular, a "standardized neurological exam" for evaluation of mutants would be a major advance. One can imagine two versions, starting with a relatively simple exam that could be performed in any Drosophila laboratory. This would be analogous to a screening exam performed by a nonspecialist physician, covering all the major neurological functions. The importance of multisystem assays is exemplified by the study of associative learning, which requires an assessment of sensory acuity and reactivity to the punishing stimulus in order to interpret behavioral deficits [Connolly and Tully, 1998 ]. While it would be desirable to devise a test not requiring sophisticated equipment, one can envision a maze-like gadget within which environmental stimuli could be controlled and fly behavior observed. Ideally, the basic test would include a behavioral overview, reminiscent of the Mini-Mental State Exam [Bassuk and Murphy, 2003] , an imperfect but rapid screening test of cognitive function that can also be used to follow individuals over time. If abnormalities were detected in the mutants on the basic test or if subtle defects were suspected based on gene expression patterns or other information, then the mutant strain could be referred to a specialty lab for further analyses. Many of the behavioral tests currently in use for Drosophila measure population responses (although courtship conditioning is assayed on individual males). Emphasis on additional single-fly tests, especially those that could be repeated on the same individual, e.g., to monitor effects of aging, would be a particularly good investment.
Another area that is poised to make rapid and very important advances is functional neuroanatomy. Until very recently, the understanding of localization of function in the Drosophila brain has been comparable to that in the mammalian brain in the mid-20th century. The correlations made between brain morphological phenotypes and behavioral deficits in mutants were analogous to structure/function studies based on postmortem studies of stroke and tumor patients many decades ago-an essential first step, but allowing only a crude, lowresolution map of functional zones with lots of question marks between them. In part because of its small size, D. melanogaster has not undergone extensive neural circuit analysis, at the level of either anatomical or functional connectivity. There has been a great temptation to extrapolate from studies in larger insects, but insects comprise extraordinarily diverse taxa and many of the cross-species assumptions have never been tested. Thus, it is very exciting that optical imaging and Drosophila genetic technology have recently converged to allow direct monitoring of neuronal activity in living preparations exposed to various stimuli [Fiala et al., 2002; Ng et al., 2002] . During the classical olfactory conditioning paradigm, one can observe rapid, shortlived spread of synaptic activity into new regions within the antennal lobes [Yu et al., 2004] . At the moment, these innovative methods have been used only for superficial regions of the brain, but that is likely to change with the incorporation of higher-sensitivity and higher-resolution microscopy.
In conclusion, the obstacles to MR therapeutics are formidable but not insurmountable. The perspective of phylogenetic conservation provides much cause for optimism that novel therapeutic strategies will emerge from a synergistic synthesis of advances in human and Drosophila neurogenetics. f
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